Lipid-Lowering Therapy

Uses

Risks & contraindications

Comparisons

Highlighted claims

• Moderate-intensity statins reduce LDL-C by about 30%, while high-intensity statins reduce LDL-C by about 50%. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
• The strike-early-and-strong strategy aims for rapid LDL-C reduction immediately after ACS. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
• Traditional stepwise lipid-lowering escalation can take up to 3 months to reach LDL-C goals, overlapping with the highest recurrent-event risk period after ACS. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
• The GDMT control arm uses a stepwise lipid management approach consistent with major US and Chinese ACS lipid guidance. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
• REPRESS uses moderate-intensity rather than high-intensity statins in comparison with several prior PCSK9 plaque studies. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial